![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C8B |
Gene summary for C8B |
![]() |
Gene information | Species | Human | Gene symbol | C8B | Gene ID | 732 |
Gene name | complement C8 beta chain | |
Gene Alias | C82 | |
Cytomap | 1p32.2 | |
Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | P07358 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
732 | C8B | NAFLD1 | Human | Liver | NAFLD | 6.20e-05 | 6.93e-01 | -0.04 |
732 | C8B | S41 | Human | Liver | Cirrhotic | 2.61e-02 | 4.84e-01 | -0.0343 |
732 | C8B | S43 | Human | Liver | Cirrhotic | 3.84e-08 | -7.23e-02 | -0.0187 |
732 | C8B | HCC1_Meng | Human | Liver | HCC | 7.03e-39 | -1.63e-01 | 0.0246 |
732 | C8B | HCC2_Meng | Human | Liver | HCC | 1.55e-07 | -2.60e-01 | 0.0107 |
732 | C8B | HCC1 | Human | Liver | HCC | 6.13e-05 | 2.93e+00 | 0.5336 |
732 | C8B | Pt13.b | Human | Liver | HCC | 3.16e-02 | -4.45e-02 | 0.0251 |
732 | C8B | S027 | Human | Liver | HCC | 4.69e-15 | 1.30e+00 | 0.2446 |
732 | C8B | S028 | Human | Liver | HCC | 5.58e-14 | 7.75e-01 | 0.2503 |
732 | C8B | S029 | Human | Liver | HCC | 1.07e-21 | 1.58e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
GO:199054218 | Oral cavity | OSCC | mitochondrial transmembrane transport | 56/7305 | 102/18723 | 8.06e-04 | 4.32e-03 | 56 |
GO:000930610 | Oral cavity | OSCC | protein secretion | 169/7305 | 359/18723 | 1.04e-03 | 5.34e-03 | 169 |
GO:004259316 | Oral cavity | OSCC | glucose homeostasis | 125/7305 | 258/18723 | 1.21e-03 | 6.08e-03 | 125 |
GO:003559210 | Oral cavity | OSCC | establishment of protein localization to extracellular region | 169/7305 | 360/18723 | 1.21e-03 | 6.08e-03 | 169 |
GO:00716929 | Oral cavity | OSCC | protein localization to extracellular region | 172/7305 | 368/18723 | 1.40e-03 | 6.79e-03 | 172 |
GO:003350016 | Oral cavity | OSCC | carbohydrate homeostasis | 125/7305 | 259/18723 | 1.44e-03 | 6.97e-03 | 125 |
GO:00515607 | Oral cavity | OSCC | mitochondrial calcium ion homeostasis | 18/7305 | 26/18723 | 1.75e-03 | 8.28e-03 | 18 |
GO:00603269 | Oral cavity | OSCC | cell chemotaxis | 146/7305 | 310/18723 | 2.13e-03 | 9.80e-03 | 146 |
GO:00716758 | Oral cavity | OSCC | regulation of mononuclear cell migration | 60/7305 | 115/18723 | 2.78e-03 | 1.21e-02 | 60 |
GO:00305959 | Oral cavity | OSCC | leukocyte chemotaxis | 110/7305 | 230/18723 | 3.86e-03 | 1.58e-02 | 110 |
GO:00507089 | Oral cavity | OSCC | regulation of protein secretion | 126/7305 | 268/18723 | 4.41e-03 | 1.79e-02 | 126 |
GO:00068514 | Oral cavity | OSCC | mitochondrial calcium ion transmembrane transport | 14/7305 | 20/18723 | 4.95e-03 | 1.94e-02 | 14 |
GO:000268810 | Oral cavity | OSCC | regulation of leukocyte chemotaxis | 62/7305 | 122/18723 | 5.22e-03 | 2.03e-02 | 62 |
GO:20004013 | Oral cavity | OSCC | regulation of lymphocyte migration | 34/7305 | 61/18723 | 5.90e-03 | 2.25e-02 | 34 |
GO:00509204 | Oral cavity | OSCC | regulation of chemotaxis | 105/7305 | 223/18723 | 8.27e-03 | 3.01e-02 | 105 |
GO:000683919 | Oral cavity | LP | mitochondrial transport | 119/4623 | 254/18723 | 1.06e-14 | 1.33e-12 | 119 |
GO:005123519 | Oral cavity | LP | maintenance of location | 111/4623 | 327/18723 | 9.62e-05 | 1.20e-03 | 111 |
GO:0051651110 | Oral cavity | LP | maintenance of location in cell | 74/4623 | 214/18723 | 7.18e-04 | 6.41e-03 | 74 |
GO:199054219 | Oral cavity | LP | mitochondrial transmembrane transport | 37/4623 | 102/18723 | 5.93e-03 | 3.53e-02 | 37 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C8B | SNV | Missense_Mutation | c.793G>A | p.Glu265Lys | p.E265K | P07358 | protein_coding | deleterious(0.03) | possibly_damaging(0.782) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
C8B | SNV | Missense_Mutation | c.709N>C | p.Tyr237His | p.Y237H | P07358 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
C8B | SNV | Missense_Mutation | rs141136423 | c.1012N>T | p.Arg338Cys | p.R338C | P07358 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C8B | SNV | Missense_Mutation | rs748983880 | c.1189G>T | p.Gly397Cys | p.G397C | P07358 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C8B | SNV | Missense_Mutation | c.1324N>C | p.Glu442Gln | p.E442Q | P07358 | protein_coding | tolerated(0.36) | benign(0.121) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
C8B | SNV | Missense_Mutation | c.1324N>C | p.Glu442Gln | p.E442Q | P07358 | protein_coding | tolerated(0.36) | benign(0.121) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
C8B | SNV | Missense_Mutation | c.1432G>A | p.Asp478Asn | p.D478N | P07358 | protein_coding | tolerated(0.19) | possibly_damaging(0.519) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
C8B | SNV | Missense_Mutation | novel | c.1340A>T | p.Asp447Val | p.D447V | P07358 | protein_coding | deleterious(0.05) | possibly_damaging(0.628) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
C8B | SNV | Missense_Mutation | rs760472969 | c.35C>T | p.Pro12Leu | p.P12L | P07358 | protein_coding | tolerated_low_confidence(0.43) | benign(0.003) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
C8B | SNV | Missense_Mutation | c.301N>G | p.Asn101Asp | p.N101D | P07358 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |